Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.35 |
| ▸ | CTSV | O60911 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 5/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CCKAR | P32238 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12299626 | 1.00 | CTSL (0.35) | CTSLCTSVCTSSCTSKHSD11B1 | |
| SCHEMBL2438546 | 0.93 | HSD11B1 (0.36) | CTSLHSD11B1CCR2 | |
| SCHEMBL12329668 | 0.93 | HSD11B1 (0.36) | CTSLHSD11B1CCR2 | |
| SCHEMBL2443150 | 0.92 | HSD11B1 (0.35) | CTSLHSD11B1CCR2 | |
| SCHEMBL12299647 | 0.92 | HSD11B1 (0.35) | CTSLHSD11B1CCR2 | |
| SCHEMBL2442467 | 0.91 | AAK1 (0.35) | HSD11B1CCR2 | |
| SCHEMBL12299605 | 0.91 | AAK1 (0.35) | HSD11B1CCR2 | |
| SCHEMBL12299624 | 0.91 | CTSL (0.39) | CTSLCCKAR | |
| SCHEMBL2440138 | 0.91 | CTSL (0.39) | CTSLCCKAR | |
| SCHEMBL2445282 | 0.90 | DRD2 (0.34) | CTSLHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399683-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110237517-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP. | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237517-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | CTSL 134/4885CTSV 175/4885CTSS 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.